Purpose Radiolabelled somatostatin-based antagonists show a higher uptake in tumour-bearing mouse models than agonists of similar or even distinctly higher receptor affinity. Very similar results were obtained with another family of G protein-coupled receptor ligands, the bombesin family. We describe a new conjugate, RM2, with the chelator DOTA coupled to D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH 2 via the cationic spacer 4-amino-1-carboxymethyl-piperidine for labelling with radiometals such as 
Introduction
Radiolabelled peptides have attracted considerable interest because of their wide applicability in the development of target-specific radiopharmaceuticals [1, 2] . Somatostatin receptor targeting is an established method to image and treat somatostatin receptor-positive tumours [3] . Generally, the good internalization properties of agonists have been considered crucial for an efficient accumulation of a radioligand in cells to give optimal tumour visualization in vivo [4, 5] . We have recently shown for somatostatin receptors 2 and 3, that antagonists have a higher tumour uptake than the corresponding agonists despite a very low internalization rate [6] . Among the different regulatory peptides explored for tumour targeting, bombesin and bombesin derivatives have attracted significant interest as they exhibit high affinity for the gastrin-releasing peptide receptor (GRPr), which is highly expressed on major human tumours such as prostate [7, 8] , breast [9, 10] and gastrointestinal stromal tumours [11] and small-cell lung cancer (SCLC) [12] . Several radiolabelled bombesin analogues have been developed and their clinical and preclinical applications in targeting GRPr-positive tumours have been reported [13] [14] [15] [16] . Bombesin elicits a broad spectrum of biological activities and may be involved as an autocrine growth factor in the pathophysiology of SCLC and other cancer types [17] .
Due to the mitogenic properties of bombesin agonists, there has been considerable interest in the design of metabolically stable and selective GRPr antagonists and in the development of radiolabelled peptides for imaging (PET, SPECT) and targeted radionuclide therapy. Several classes of bombesin antagonists have been explored by the modification of the C-terminal residues of naturally amidated bombesin agonists [18, 19] . Cescato et al. [20] demonstrated the superiority of 99m Tc-demobesin1 as a tumour-targeting agent with respect to a comparably potent radioagonist. Further, Abd-Elgaliel et al. [21] ]-BBN (6) (7) (8) (9) (10) (11) (12) (13) (14) conjugate, supporting the use of radiolabelled bombesin antagonists as potential candidates for in vivo imaging of GRPr-positive tumours. Very recently, we reported a direct comparison of a potent radiolabelled statin-based antagonist 111 In-RM1 and the potent agonist 111 In-AMBA [22] . Despite the lower GRPr affinity, the radioantagonist showed higher tumour uptake and superior pharmacokinetics than the radioagonist.
We describe here the synthesis and the pharmacological evaluation of a new DOTA-conjugated bombesin antagonist, RM2 (DOTA-4-amino-1-carboxymethyl-piperidine-D-PheGln-Trp-Ala-Val-Gly-His-Sta-Leu-NH 2 ), supporting our hypothesis of the superiority of G protein-coupled receptor antagonists over agonists in vivo. We have shown earlier that positive charges at the N-terminal of bombesin-based agonists (BN (7) (8) (9) (10) (11) (12) (13) (14) ) lead to improved bombesin receptor affinities (Zhang H.; PhD thesis, University of Basel, 2006. http://edoc.unibas.ch/586). We were interested to determine if a similar effect could also be seen when employing antagonists. Therefore we linked DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) [23] via a positively charged spacer (4-amino-1-carboxymethyl-piperidine) to the potent antagonist JMV594 [24] and evaluated the use of the In-labelled conjugate for SPECT and the 68 Ga-labelled peptide for PET. The antagonistic properties of the conjugate were evaluated in vitro using an immunofluorescence-based internalization assay and inhibition of Ca 2+ mobilization assay using agonists. We were interested to determine if there is a difference between the use of an androgendependent and an androgen-independent tumour xenograft. Therefore its pharmacokinetics were studied in PC-3 and LNCaP tumour-bearing nude mice using SPECT/CT and PET/CT.
Materials and methods

Chemicals
All chemicals were obtained from commercial sources and used without additional purification. Rink amide 4-methyl-benzhydrylalanine (MBHA) resin and all the Fmoc-protected amino acids are commercially available from NovaBiochem (Laeufelfingen, Switzerland), DOTA ( t Bu) 3 from Chematec (Dijon, France), Fmoc-4-amino-1-carboxymethyl-piperidine from NeoMPS (Strasbourg, France) and 111 InCl 3 from Covidien Medical (Petten, The Netherlands). BIM26226 [25] was provided by Ipsen Biotech (Paris, France). Electrospray ionization mass spectroscopy (ESI-MS) was carried out with a Finnigan SSQ 7000 spectrometer (Bremen, Germany). Analytical highperformance liquid chromatography (RP-HPLC) was performed on a Hewlett Packard 1050 HPLC system with a multiwavelength detector and a flow-through Berthold LB 506 Cl γ-detector using a Macherey-Nagel Nucleosil 120 C 18 column (Oensingen, Switzerland) (eluent A comprising 0.1% TFA in water, eluent B comprising acetonitrile; gradient 0-30 min, 95% to 55% A; flow 0.750 ml/min). Semipreparative RP-HPLC was performed on a Metrohm HPLC system LC-CaDI 22-14 (Herisau, Switzerland) with a Macherey-Nagel VP 250/21 Nucleosil 100-5 C 18 column (eluent A comprising 0.1% TFA in water, eluent B comprising acetonitrile; gradient: 0-20 min, 95% to 30% A; flow 15 ml/min). Quantitative gamma counting was performed on a COBRA 5003 γ-system well counter from Packard Instruments.
Human embryonic kidney 293 (HEK293) cells, stably expressing the HA epitope-tagged human GRPr (HEKGRPr), were generated as previously described [20] and cultured at 37°C in an atmosphere containing 5% CO 2 in DMEM with GlutaMAX-I containing 10% (v/v) fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin and 750 μg/ml G418. Human prostate cancer cells (PC-3) were obtained from ATCC (Manassas, VA), cultured in DMEM or in Ham's F-12 K medium, supplemented with vitamins, amino acids, penicillin/streptomycin and 10% FBS in a humidified atmosphere containing 5% CO 2 at 37°C. LNCaP cells were cultured in RPMI 1640 medium supplemented with 1nM of synthetic androgen R1881 (NEN), amino acids, penicillin/ streptomycin, sodium pyruvate and 10% FBS in a humidified atmosphere containing 5% CO 2 at 37°C. All culture reagents were from Invitrogen (Basel, Switzerland) or from BioConcept (Allschwil, Switzerland).
Synthesis of peptide conjugate and metallation
The peptide-chelator conjugate RM2 was synthesized manually according to standard Fmoc chemistry [26] using Rink amide MBHA resin. The spacer and the prochelator DOTA( t Bu) 3 were consecutively coupled to the peptide with HATU as activating agent. The peptide conjugate was purified according to the method of Heppeler et al. [23] . The peptide was purified by RP-HPLC and characterized by ESI-MS. The conjugate was complexed with nat InCl 3 using a previously described procedure [14] . The pure product (yields ranging from 70% to 80%) after lyophilization was analysed by analytical RP-HPLC and characterized by ESI-MS. GaCl 3 solution (400 μl, 200-240 MBq; 97.6% acetone/ 0.05 M HCl) was added and the pH adjusted to 3.6-3.9. The solution was heated in a microwave at 75 W (95°C) for four times for 30 s each time and with 30 s between each heating. The reaction mixture was diluted with 5 ml of water and purified through a SepPak C18 cartridge preconditioned as described previously [27] . The product was eluted with EtOH (500 μl) and the radiochemical purity was checked by HPLC and instant thin-layer chromatography.
Receptor binding affinity and selectivity IC 50 values of RM2 and nat In-RM2 were determined by in vitro GRPr autoradiography on cryostat sections of wellcharacterized prostate carcinomas as described previously [7, 28] (6) (7) (8) (9) (10) (11) (12) (13) (14) as universal bombesin receptor ligand. The binding affinity profile for the three bombesin receptor subtypes was determined as described in detail previously [30] .
The cellular binding saturation experiments were performed using increasing concentrations of the 111/nat
In-DOTA peptide ranging from 0.1 to 1000 nmol/l. Confluent PC-3 cells were seeded into six-well plates (about 1. ]BN(6-13) OMe) [25] was used. For each radioligand, triplicates were prepared for every concentration, for both total binding and nonspecific binding. Before adding the radioligands to the wells, the plates were placed on ice for 30 min. After adding the radioligands and BIM26226 for nonspecific binding, the plates were incubated for 2 h at 4°C. The binding buffer was then aspirated and the cells were washed twice with ice-cold phosphate-buffered saline (pH 7.4); this represented the free fraction. Finally, the cells were collected with 1 N NaOH; this corresponded to the bound fraction. Specific binding was calculated by subtracting nonspecific from total binding at each concentration of radioligand. Affinity (K d ) and binding site density (B max ) were calculated from Scatchard plots using Origin 7.5 software (Microcal Software, Northampton, MA).
Internalization
For internalization experiments, approximately 3 kBq of 111/nat In-labelled peptide (0.25 pmol) was added to the medium and the cells were incubated (in triplicate) for 0.5, 1, 2 and 4 h at 37°C in an atmosphere containing 5% CO 2. A large excess of BIM26226 was used (2 μmol/l, 100 μl) to determine nonspecific internalization. At each time point the cells were treated as recently described [14] .
Immunofluorescence microscopy
Immunofluorescence microscopy-based internalization assays with HEK-GRPr cells were performed as previously described [20] . HEK-GRPr cells were treated with either 10 nmol/l bombesin or 1 μmol/l RM2 or, to evaluate potential antagonism, with 10 nmol/l bombesin in the presence of a 100-fold excess of RM2 for 30 min at 37°C in an atmosphere containing 5% CO 2 in growth medium, and then processed for immunofluorescence microscopy using first mouse monoclonal HA-epitope antibody (Covance, Berkeley, CA) at a dilution of 1:1000 and second Alexa Fluor 488 goat anti-mouse IgG (H + L, Molecular Probes, Eugene, OR) at a dilution of 1:600. The cells were imaged using a Leica DM RB immunofluorescence microscope and an Olympus DP10 camera.
Ca
2+ mobilization assay Intracellular Ca 2+ mobilization was measured in PC-3 cells using a Fluo-4NW calcium assay kit (Molecular Probes, Eugene, OR) as described previously [20] . In brief, PC-3 cells were seeded (10,000 cells per well) into 96-well plates and cultured for 2 days at 37°C in an atmosphere containing 5% CO 2 . On the day of the experiment, the cells were washed with assay buffer (1 × HBSS, 20 mmol/l HEPES) containing 2.5 mmol/l probenecid. The cells were then incubated with 100 μl/well Fluo-4NW dye in assay buffer for 30 min at 37°C in an atmosphere containing 5% CO 2 and then for a further 30 min at room temperature. The dye-loaded cells were transferred to a SpectraMax M2 e (Molecular Devices, Sunnyvale, CA) and intracellular Ca 2+ mobilization was recorded in a kinetic experiment for 60 s at room temperature monitoring fluorescence emission at 520 nm (λ ex =485 nm) in the presence of the compounds to be tested. Data are shown as percentage of the maximum calcium response obtained with ionomycin as reported previously [20] .
Biodistribution experiments
All animal experiments were performed in compliance with the Swiss (no. 798) and German regulations for animal treatment.
The pharmacokinetics of 111 In-RM2 were evaluated in female nude mice (3 weeks old), implanted subcutaneously with 10 million PC-3 tumour cells, freshly expanded in a sterilized solution of phosphate-buffered saline (pH 7.4). The mice (20-22 g ) were injected into the tail vein 11 days after inoculation with 10 pmol of radiolabelled peptides (about 0.18 MBq, 100 μl). For the determination of nonspecific uptake in tumour or receptor-positive organs, a group of four animals were preinjected (5 min) with 0.02 μmol of unlabelled peptide. At 1, 4, 24, 48 and 72 h the mice (in groups of 4 to 11) were killed and organs of interest were collected, rinsed, blotted, weighed and counted in a γ-counter. The percentage of injected activity per gram (%IA/g) was calculated for each tissue.
The biodistribution experiments with 68 Ga-RM2 were performed using male nude mice (NMRI nu/nu, Taconic) at 3-4 weeks of age. The animals were implanted subcutaneously with PC-3 (2×10 6 cells/mouse) or LNCaP cells (1×10 7 cells/mouse) in the right shoulder. Mice to be injected with LNCaP cells were pretreated with testosterone pellets (12.5 mg, 90 days release; IRA, Sarasota, FL) implanted 3-4 days before tumour cell inoculation. For the tumour cell implantation, cells were suspended in Matrigel (BD Biosciences) to a final volume of 100 μl. The animals (30-35 g) were injected intravenously 4 weeks after implantation with 80 pmol of 68 Ga-RM2 (100 μl, 150-240 kBq). The animals were killed at different times from 20 to 120 min after injection (three mice for each time point). In addition, a group of three mice were preinjected with 0.06 μmol of RM2 and killed at 1 h later to determine nonspecific uptake.
Imaging SPECT/CT was performed with a four-head multiplexing multipinhole camera (NanoSPECT/CT; Bioscan). Each head was equipped with a tungsten-based collimator of nine 1.4-mm diameter pinholes. The apertures used in this study provided a reconstructed resolution in the submillimetre range at 140 keV [31] . Two PC-3 tumour-bearing nude mice were anaesthetized with 4% isoflurane/oxygen 24 h after intravenous injection of 42 MBq of 111 In-RM2. The acquisition mode was helical for both modalities and the time per view for the SPECT scans was 30 s. The acquisition time was approximately 15 min for the SPECT scan. CT scans were performed with an integrated CT scanner using a tube voltage of 45 kV and an exposure time of 1,500 ms per view. After acquisition, the SPECT data were reconstructed iteratively with HiSPECT software (Scivis). The CT data were reconstructed using a conebeam filtered back-projection. The SPECT and CT data were automatically coregistered as both modalities shared the same axis of rotation. The fused datasets were analysed in InVivoScope postprocessing software (Bioscan).
The PET/CT studies were performed using a multimodality Inveon PET/CT camera (Siemens). Approximately 50 min after intravenous injection of about 7 MBq 68 Ga-RM2 (400 pmol) PC-3 and LNCaP tumour-bearing mice were anaesthetized with 4% isoflurane/oxygen. At a constant low breathing frequency (about 60 min -1 ) animals were transferred to the camera bed and fixed for static PET imaging with a duration of 30 min followed by CT. Breathing frequency and body temperature of the animals were continuously monitored. Images were recorded, reconstructed and analysed using Inveon-specific acquisition and research software packages. Fig. 1) (Fig. 2b) . The K d value was 2.9±0.4 nmol/l while the B max value was 1.1±0.05 nmol/l. This B max value corresponding to 5.5×10 5 binding sites per cell is in agreement with literature data [32] .
Results
RM2 (
The antagonistic properties of RM2 were confirmed by a immunofluorescence-based internalization assay using HEK-GRPr cells. Figure 3 shows that 10 nmol/l bombesin was able to trigger receptor internalization into HEK-GRPr cells. RM2 was not able to stimulate GRPr internalization even at a concentration of 1,000 nmol/l. However, at a concentration of 1,000 nmol/l together with 10 nmol/l of bombesin, the peptide was able to prevent the bombesininduced receptor internalization. The Ca 2+ mobilization assay was performed to determine dose-response curves of the bombesin antagonist in PC-3 cells. RM2 behaved as an antagonist shifting the dose-response curve of bombesin to a higher molar range when present at a concentration of 10 μmol/l together with bombesin. Moreover, tested alone at 1 μmol/l and 10 μmol/l the peptide had no effect on intracellular calcium mobilization (Fig. 4) .
Biodistribution data from PC-3 tumour-bearing athymic nude mice are shown in Table 2 .
111 In-RM2 displayed fast blood clearance with 0.05±0.04 %IA/g remaining in the blood at 4 h after injection. The uptake in the organs of the gastrointestinal tract, which are known to express GRPr, such as the pancreas, stomach and intestine, was high and specific, but the radiopeptide was washed out quickly. The pancreas uptake decreased rapidly from 22.6±4.7%IA/g at 1 h to 1.5±0.5%IA/g at 4 h. High uptake was observed in the PC-3 tumour with 15.2±4.8%IA/g at 1 h and the uptake was still high at 4 h with 11.7±2.4%IA/g, and even at later time points (6.8±1.0 %IA/g at 24 h; 4.7±0.4%IA/g at 48 h; 4.1±0.3%IA/g at 72 h). The long retention in the tumour indicates that RM2 labelled with 177 Lu or 90 Y may be a successful therapeutic agent.
The radiopeptide was quickly washed out from nontarget tissues leading to very high tumour to normal organ ratios which increased over time. For instance, tumour to kidney Uptake in the GRPr rich tissues, as well as in the tumour, were found to be significantly reduced in the animals preinjected with an excess of cold peptide, indicating a specific GRPr-mediated uptake. The pharmacokinetics of 68 Ga-RM2 was studied in male nude mice bearing the androgen-independent PC-3 xenograft reported to show high GRPr expression (Table 3) or the androgen-dependent LNCaP xenograft that shows about 40-fold lower GRPr expression (Table 4 ) [33] . In PC-3 tumour-bearing mice Fig. 4 Dose-response curves of the bombesin analogue RM2 determined by the Ca 2+ mobilization assay. PC-3 cells were treated either with bombesin at concentrations ranging between 0.01 nM and 10 μM alone (circles), or with bombesin at the same concentrations together with 10 μM of the bombesin analogue RM2 (squares). RM2 behaves as an antagonist shifting the dose-response curve of bombesin to a higher molar range. When tested alone, RM2 at a concentration of 10 μM (triangles) has no effect on calcium mobilization in PC-3 cells high accumulation was found in the tumour (9.6±1.4%IA/g at 20 min). The uptake in the tumour increased with time reaching a maximum value of 14.7±2.1%IA/g at 80 min, while decreasing in the GRPr-positive organs (45.9±4.7% IA/g at 20 min and 22.4±6.6%IA/g at 80 min in the pancreas). The kidney uptake was comparable to the tumour uptake at 20 min, but decreased significantly; at 80 min the tumour to kidney ratio was 6. Most likely due to their lower GRPr expression status [34] , LNCaP tumours showed lower uptake at each time point resulting in decreased tumour to target tissue ratios. The 68 Ga-RM2 was quickly cleared from the nontarget tissue and the blood. These pharmacokinetic data are reflected in the microPET/CT images presented in Fig. 6 . Maximum intensity projections in PC-3 and LNCaP mice (unblocked and blocked with 100 μg RM2 per mouse) show the 
Discussion
The use of radiolabelled peptide antagonists for receptor targeting of tumours in vivo has attracted attention since the seminal paper of Ginj et al. [6] . It was shown that compared with agonists, somatostatin receptor antagonists are superior in terms of targeting more receptor binding sites and consequently demonstrate higher tumour uptake. Based on these results research groups have focused their attention on the development of new radioantagonists for tumour targeting [20, 21, 35] . Despite this progress little is known about structural parameters determining the antagonistic potential of radiometal-labelled bombesin-based antagonists, such as the influence of the metal complex, the spacer separating the reporting unit from the pharmacophoric peptide, receptor subtype profile etc. In addition, the origin of the long residence time in tumours found by us and others [20, 22] is not yet known.
We report here on the development of a DOTAconjugated radiopeptide for the diagnosis and therapy of bombesin receptor-positive tumours. The DOTA monoamide coupled chelator can form complexes with a variety of trivalent and divalent radiometals to produce radiolabelled bioconjugates with high in vitro and in vivo stability [23] . In our previous work, the statin-based bombesin antagonist was linked via Gly-aminobenzoic acid to DOTA for a direct comparison with the potent agonist AMBA [22] . In order to potentially improve the pharmacological performance, a statin analogue was coupled to the positively charged spacer 4-amino-1-carboxymethyl piperidine. The K d and the IC 50 values of nat In-RM2 are indeed 3-fold and 1.5-fold higher, respectively, than those of RM1 [22] , indicating that positive charges may be a structural motif to increase binding affinity (Table 1) . Excellent antagonist properties of RM2 were confirmed by immunofluorescence and Ca 2+ mobilization assays. The presence of a low concentration of RM2 inhibits the receptor internalization triggered by bombesin. In addition, the mobilization of Ca 2+ caused by agonists was efficiently inhibited by RM2.
The pharmacokinetics of 111 In-RM2 were studied in PC-3 tumour-bearing nude mice. The radioconjugate was taken up by the tumour and the receptor-positive organs at early time points but it was washed out at a different rate; the pancreas uptake decreased by a factor of 14.6 within 4 h while the tumour uptake decreased by a factor of only 1.3 over the same time period. The uptake was specific and receptor-mediated; more than 95% of the uptake in the tumour and in the pancreas was blocked by preinjection of 20 nmol RM2. The fast clearance from the abdominal organs, including the pancreas, is consistent with the few reported data of bombesin-based radioantagonists [20] [21] [22] and it differs distinctly from the in vivo behaviour of the agonists that show high and persistent uptake in the abdominal organs [14] [15] [16] 36] . The reason for the different pharmacokinetic behaviour is not understood yet. It may be due to species differences (PC-3 is of human origin), or may result from a more efficient perfusion in the pancreas and intestine. The slow washout of 111 In-RM2 from the tumour is in contrast to that of 111 In-bomproamide [21] which showed as much as 70% loss within 4 h of injection. 111 In-Bomproamide also shows faster washout from the abdominal organs leading to similar tumour to background ratios. Despite the fact that 111 In-RM2 has an additional positive charge and threefold greater K d value than our previously reported radioantagonist [22] , we found little improvement in regard to overall pharmacokinetics except for a lower liver uptake leading to a significantly higher tumour to liver ratio.
The excellent tumour to kidney and tumour to background ratios led us to study this analogue as a PET imaging tool. We tested it in two animal models and with two different cell lines. The peptide was labelled with 68 Ga and studied in PC-3 and LNCaP tumour-bearing male nude mice. The PC-3 cell line is more representative of androgen-independent tumour cells while the LNCaP cell line is, currently, the closest representation of a human prostatic carcinoma in cell culture [37, 38] kinetics of 68 Ga-RM2 in PC-3 tumours reflect what we observed with 111 In-RM2. Uptake in the tumour, in the target tissues and in the kidney was high at early time points but it decreased rapidly in all organs except the tumour. The biodistribution data of the LNCaP tumourbearing nude mice showed similar pharmacokinetics but with lower tumour uptake. The lower tumour uptake is in line with the significant difference in the number of binding sites of the two cell lines [34] . In all cases the high tumour uptake and the high tumour to kidney ratio of 68 Ga-RM2 are well visualized in the PET/CT images of the PC-3 and LNCaP tumour-bearing nude mice. The ability of this conjugate, and more generally, of many antagonists already studied, to reach and maintain high tumour accumulation despite the low internalization may be due to strong receptor-antagonist interactions that produce a stable complex [39] .
111/nat In-RM2 behaved as an antagonist in several types of in vitro internalization experiments, showing a very poor receptor-mediated internalization in contrast to high surface binding. It prevented bombesin-induced receptor internalization in the immunofluorescence-based internalization experiment. The high and specific tumour uptake and the good tumour to background ratio at each time point indicate that this analogue is a good candidate for diagnostic purposes (PET/CT, SPECT/CT) and is potentially a good candidate for human studies.
